Biosimilars Can't Circumvent BPCIA With Litigation
December 13, 2013, 2:59 PM EST
Law360, New York (December 13, 2013, 2:59 PM EST) -- The United States District Court for the Northern District of California ruled on Nov. 12, 2013, that a party seeking to obtain approval of a biosimilar could not avoid the process set forth in the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) by obtaining a declaratory judgment of patent invalidity before even submitting a biosimilars application. See Sandoz Inc. v. Amgen Inc., Civil No. 13-2894 MMC, (N.D. Cal. 2013).
Biosimilars are follow-on products that reference an approved biologic product (a “Reference Product” or “RP”)...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.